Stock listing
NASDAQ:AVBP ArriVent BioPharma, Inc. Stock
Home listing (NASDAQ) of ArriVent BioPharma, Inc.
Follow ArriVent BioPharma, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:AVBP
$10.52 USD -0.38 (-3.5%)
Close on Nov 20, 2026
- Day range
- $10.38 – $11.35 USDNov 20, 2026
- Volume
- 1.05M sharesNov 20, 2026
- Market cap
- $544.1M USDAt the close on Nov 20, 2026 · price × 51.72M shares outstanding
- 52-week range
- $10.33 – $35.83 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $24.59M USDMedian day 817,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:AVBP · Home | $10.52 USD | -0.38 (-3.5%) | 1,053,366 | $10.93 | $11.35 | $10.38 | $10.90 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:AVBP · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $10.52 | -0.38 | -3.5% | $10.93 | $11.35 | $10.38 | 1,053,366 | |
| $10.90 | +0.21 | +2.0% | $10.42 | $11.11 | $10.33 | 2,696,657 | |
| $10.69 | -0.87 | -7.5% | $11.57 | $11.87 | $10.50 | 863,852 | |
| $11.56 | -1.45 | -11.1% | $12.86 | $13.14 | $11.55 | 644,206 | |
| $13.01 | -0.06 | -0.5% | $13.00 | $13.24 | $12.59 | 616,140 | |
| $13.07 | -0.435 | -3.2% | $13.55 | $13.60 | $12.89 | 793,945 | |
| $13.51 | +0.015 | +0.1% | $13.62 | $13.91 | $13.38 | 910,925 | |
| $13.49 | -0.67 | -4.7% | $14.25 | $15.05 | $13.21 | 776,294 | |
| $14.16 | +0.52 | +3.8% | $13.86 | $14.60 | $13.50 | 905,949 | |
| $13.64 | +1.41 | +11.5% | $12.40 | $13.88 | $12.00 | 1,400,448 | |
| $12.23 | -1.26 | -9.3% | $13.39 | $13.50 | $12.18 | 1,101,682 | |
| $13.49 | +0.47 | +3.6% | $13.39 | $13.57 | $12.47 | 1,624,627 | |
| $13.02 | -0.33 | -2.5% | $13.47 | $13.94 | $13.01 | 1,226,259 | |
| $13.35 | -1.52 | -10.2% | $14.89 | $14.98 | $13.26 | 1,237,292 | |
| $14.87 | -1.08 | -6.8% | $15.78 | $16.17 | $14.33 | 1,194,900 | |
| $15.95 | +0.22 | +1.4% | $15.87 | $16.42 | $15.73 | 658,000 | |
| $15.73 | +0.33 | +2.1% | $15.67 | $15.89 | $15.20 | 990,000 | |
| $15.40 | +0.04 | +0.3% | $15.45 | $15.69 | $15.00 | 1,582,000 | |
| $15.36 | -5.64 | -26.9% | $18.14 | $18.16 | $14.78 | 5,946,900 | |
| $21.00 | +1.80 | +9.4% | $19.00 | $21.23 | $18.18 | 3,277,900 | |
| $19.20 | +0.08 | +0.4% | $18.93 | $19.68 | $18.78 | 843,700 | |
| $19.12 | +0.27 | +1.4% | $19.07 | $19.44 | $18.68 | 1,489,200 | |
| $18.85 | +0.91 | +5.1% | $17.94 | $18.98 | $17.57 | 817,800 | |
| $17.94 | +1.28 | +7.7% | $16.82 | $18.14 | $16.73 | 1,013,200 | |
| $16.66 | -0.13 | -0.8% | $16.86 | $17.23 | $16.49 | 1,334,000 | |
| $16.79 | +0.59 | +3.6% | $16.40 | $16.91 | $15.97 | 814,900 | |
| $16.20 | +0.11 | +0.7% | $16.06 | $16.62 | $15.26 | 1,589,100 | |
| $16.09 | -0.37 | -2.2% | $16.28 | $16.72 | $15.95 | 1,968,300 | |
| $16.46 | -0.27 | -1.6% | $16.57 | $16.78 | $16.26 | 1,335,400 | |
| $16.73 | +0.02 | +0.1% | $16.59 | $17.76 | $16.49 | 1,731,100 | |
| $16.71 | -0.18 | -1.1% | $16.62 | $16.91 | $15.78 | 2,154,200 | |
| $16.89 | +1.80 | +11.9% | $15.25 | $17.35 | $14.97 | 4,332,600 | |
| $15.09 | -13.37 | -47.0% | $12.09 | $15.79 | $11.36 | 19,742,400 | |
| $28.46 | +0.19 | +0.7% | $28.00 | $28.70 | $27.02 | 494,800 | |
| $28.27 | -0.66 | -2.3% | $29.26 | $29.33 | $27.80 | 507,600 | |
| $28.93 | -1.35 | -4.5% | $29.99 | $30.64 | $28.81 | 591,800 | |
| $30.28 | +0.74 | +2.5% | $29.69 | $30.90 | $29.65 | 712,500 | |
| $29.54 | +0.24 | +0.8% | $29.30 | $30.05 | $28.80 | 780,000 | |
| $29.30 | +0.85 | +3.0% | $28.38 | $29.90 | $28.02 | 1,016,600 | |
| $28.45 | -1.65 | -5.5% | $30.16 | $30.55 | $28.43 | 653,200 | |
| $30.10 | -0.20 | -0.7% | $29.94 | $30.51 | $29.24 | 609,000 | |
| $30.30 | -0.02 | -0.1% | $30.32 | $31.49 | $29.84 | 1,206,000 | |
| $30.32 | +0.58 | +2.0% | $30.22 | $30.50 | $29.56 | 389,100 | |
| $29.74 | +0.84 | +2.9% | $29.17 | $31.16 | $28.20 | 937,000 | |
| $28.90 | +0.54 | +1.9% | $29.00 | $29.64 | $28.62 | 1,238,500 | |
| $28.36 | +0.71 | +2.6% | $28.24 | $28.45 | $27.84 | 456,400 | |
| $27.65 | -0.32 | -1.1% | $28.15 | $28.31 | $27.28 | 379,400 | |
| $27.97 | -0.60 | -2.1% | $28.51 | $28.75 | $27.70 | 337,300 | |
| $28.57 | -0.43 | -1.5% | $29.10 | $29.83 | $28.40 | 538,300 | |
| $29.00 | +0.30 | +1.0% | $29.16 | $29.21 | $28.15 | 1,132,000 | |
| $28.70 | -1.09 | -3.7% | $29.33 | $30.53 | $28.54 | 564,200 | |
| $29.79 | -0.49 | -1.6% | $30.02 | $30.26 | $29.40 | 280,100 | |
| $30.28 | -0.67 | -2.2% | $30.57 | $31.40 | $30.02 | 722,000 | |
| $30.95 | -0.08 | -0.3% | $30.79 | $31.45 | $30.60 | 182,400 | |
| $31.03 | +0.52 | +1.7% | $30.58 | $31.39 | $30.22 | 465,400 | |
| $30.51 | +0.36 | +1.2% | $30.33 | $30.79 | $29.60 | 423,900 | |
| $30.15 | +0.10 | +0.3% | $30.10 | $30.33 | $29.70 | 356,100 | |
| $30.05 | -0.12 | -0.4% | $29.94 | $30.26 | $29.35 | 369,600 | |
| $30.17 | -0.83 | -2.7% | $30.53 | $31.37 | $29.75 | 353,500 | |
| $31.00 | -0.14 | -0.4% | $30.79 | $31.77 | $30.24 | 300,000 | |
| $31.14 | -0.21 | -0.7% | $31.21 | $31.41 | $30.11 | 433,800 | |
| $31.35 | +3.09 | +10.9% | $28.64 | $31.52 | $28.64 | 961,653 | |
| $28.26 | -0.86 | -3.0% | $29.02 | $29.02 | $28.05 | 225,594 | |
| $29.12 | -0.06 | -0.2% | $29.45 | $29.77 | $28.95 | 304,800 | |
| $29.18 | -0.84 | -2.8% | $29.73 | $29.81 | $28.64 | 406,300 |
- Ticker
- NASDAQ:AVBP
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 9, 2026
ArriVent BioPharma Reports Third Quarter 2026 Financial Results
Latest deck · August 2026
Investor Presentation (August 2026)
Investor deck · 21 slides
Latest news
ArriVent BioPharma Reports Third Quarter 2026 Financial Results
Nov 9, 2026
Closed $13.49 (-4.7%) on Nov 10, 2026
ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026
Oct 25, 2026
Closed $15.36 (-26.9%) on Oct 26, 2026
ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer
Oct 19, 2026
Closed $17.94 (+7.7%) on Oct 19, 2026
ArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002
Oct 12, 2026
Closed $16.09 (-2.2%) on Oct 13, 2026
ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC
Oct 6, 2026
Closed $15.09 (-47.0%) on Oct 6, 2026
ArriVent BioPharma Reports Second Quarter 2026 Financial Results
Aug 12, 2026
Closed $30.00 (-4.6%) on Aug 13, 2026
ArriVent BioPharma Reports First Quarter 2026 Financial Results
May 11, 2026
Closed $29.02 (-1.6%) on May 11, 2026
ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers
May 7, 2026
Closed $28.85 (-2.6%) on May 7, 2026
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting
Mar 17, 2026
Closed $22.81 (-5.0%) on Mar 18, 2026
ArriVent BioPharma Reports Full Year 2025 Financial Results
Mar 5, 2026
Closed $25.25 (-4.9%) on Mar 5, 2026
ArriVent BioPharma, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 12 in the last 12 months · 34 in all · newest Nov 9, 2026 · oldest 2024
- Decks
- 4 decks · latest August 2026
Where ArriVent BioPharma, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:AVBP · Home listing · This page | NASDAQ | United States | USD |
| BOATS:AVBP | BOATS | United States | USD |
Valuation
EV/sales 30.2× against a median of 44.8×: 3rd lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $151.2M USD
- P/E
- Loss
- EV/sales
- 30.2×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.4×
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.18
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| ArriVent BioPharma, Inc. · NASDAQ:AVBP | US$544.1M | US$151.2M | n/a | 30.2× | n/a | 1.4× | n/a | 0.0× | 1.18 |
| Entera Bio Ltd. · NASDAQ:ENTX | US$574.8M | US$308.9M | n/a | n/a | n/a | 2.1× | n/a | 0.0× | 0.76 |
| DBV Technologies SA · EURONEXT:DBV | US$572.0M | US$430.9M | n/a | 47.1× | n/a | 3.9× | n/a | 0.1× | n/a |
| Ascletis Pharma, Inc. · HKEX:1672 | US$571.4M | US$231.7M | n/a | 761× | n/a | 1.7× | n/a | 0.0× | n/a |
| 4D Molecular Therapeutics, Inc. · NASDAQ:FDMT | US$565.1M | US$277.8M | n/a | 2.9× | n/a | 1.7× | −208.6% | 0.1× | 1.75 |
| Bicara Therapeutics Inc. · NASDAQ:BCAX | US$560.3M | US$118.8M | n/a | n/a | n/a | 1.4× | n/a | 0.0× | 1.37 |
| Lepu Biopharma Co. Ltd. Class H · HKEX:2157 | US$554.9M | US$613.6M | 14.5× | 4.5× | 22.9× | 2.6× | 28.0% | 0.8× | n/a |
| Aclaris Therapeutics, Inc. · NASDAQ:ACRS | US$545.6M | US$431.3M | n/a | 67.4× | n/a | 3.3× | n/a | 0.0× | 1.42 |
| Surrozen, Inc. · NASDAQ:SRZN | US$542.5M | US$448.0M | n/a | 42.5× | n/a | n/a | n/a | n/a | 1.64 |
| Climb Bio, Inc. · NASDAQ:CLYM | US$539.8M | US$335.4M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 1.44 |
| Abbisko Cayman Limited · HKEX:2256 | US$519.0M | US$228.1M | n/a | n/a | n/a | 1.6× | n/a | 0.2× | n/a |
| Median of the others | US$557.6M | US$322.2M | 14.5× | 44.8× | 22.9× | 2.1× | −90.3% | 0.0× | 1.43 |
Forecasts
11 strong buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 26.10 USD · Analysts' mean
- EPS, year to Dec 2026
- -4.05 · 9 analysts
- Revenue, year to Dec 2026
- 5M · 5 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Zhengbin Yao | Chairman, Chief Executive Officer |
| Winston Kung | Chief Financial Officer |
| Robin LaChapelle | Chief Operating Officer |
| James Kastenmayer | General Counsel |
| Brent Rice | Chief Commercial Officer |
| Yang Wang | Chief Technology Officer |
Board
| Director | Role |
|---|---|
| Zhengbin Yao | Chairman, Chief Executive Officer |
| Chris Nolet | Director |
| James Healy | Director |
| John Hohneker | Director |
| Kristine Peterson | Lead Independent Director |
| Merdad Parsey | Director |
| Stuart Lutzker | Director |
Events
- Next results
- Mar 8, 2027 (expected)
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 9, 2026 · After close | −4.7% |
| Q2 2026 | Aug 12, 2026 | −4.4% |
| Q1 2026 | May 11, 2026 · After close | −0.2% |
| Q4 2025 | Mar 26, 2026 | −5.8% |
| Q3 2025 | Nov 10, 2025 · Before open | +3.1% |
| Q2 2025 | Aug 11, 2025 · Before open | −3.3% |
| Q1 2025 | May 12, 2025 · Before open | −0.8% |
| Q4 2024 | Mar 3, 2025 | −7.0% |
| Q3 2024 | Nov 14, 2024 · Before open | −11.9% |
| Q2 2024 | Aug 14, 2024 · After close | −0.4% |
All 12 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 8, 2024 · Before open | +0.6% |
| Q4 2023 | Mar 28, 2024 · After close | +2.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2026) | Investor deck | 21 slides | August 2026 |
| Investor Presentation (June 2025) | Investor deck | 25 slides | Jun 23, 2025 |
| Technical Presentation (September 2024) | Technical | 13 slides | Sep 8, 2024 |
| European Lung Cancer Congress 2022 | Conference | 12 slides | Mar 18, 2022 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock and pre-funded warrants Announced: US$75M · US$19.5 a share · Goldman Sachs & Co. LLC +7 Dealers: Goldman Sachs & Co. LLC (co-lead), Citigroup (co-lead), Guggenheim Securities (co-lead), LifeSci Capital, Oppenheimer & Co., B. Riley Securities, H.C. Wainwright & Co., Jones Use of proceeds: Support activities for firmonertinib and other pipeline programs, working capital and general corporate purposes | Jul 1, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$18.00 a share on Jan 25, 2024.
- Price
- US$18.00 a share
- Shares offered
- 9,722,222 shares of common stock
- Offering size
- US$175 million
- Underwriters' option
- Up to 1,458,333 more shares
- Listing
- AVBP on the Nasdaq Global Market
- Underwriters
- Goldman Sachs & Co. LLC, Jefferies, Citigroup, LifeSci Capital · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Aug 25, 2023 |
| Filed publicly | Jan 5, 2024 |
| Amended twice | Newest Jan 23, 2024 |
| Shares registered with an exchange | Jan 23, 2024 |
| Declared effective by the SEC | Jan 25, 2024 |
| Final prospectus, with the price | Jan 26, 2024 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jan 26, 2024 |
| EFFECT · Notice that a registration is effective | Jan 25, 2024 |
| S-1MEF · Registration of more shares for the same offering | Jan 25, 2024 |
| CERT · Exchange's certificate of listing | Jan 25, 2024 |
| S-1/A · Registration statement, amended | Jan 23, 2024 |
| 8-A12B · Registration of shares for listing on an exchange | Jan 23, 2024 |
| CORRESP · Letter to the SEC | Jan 23, 2024 |
| CORRESP · Letter to the SEC | Jan 23, 2024 |
| CORRESP · Letter to the SEC | Jan 22, 2024 |
| S-1/A · Registration statement, amended | Jan 22, 2024 |
All 23 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | Jan 12, 2024 |
| CORRESP · Letter to the SEC | Jan 11, 2024 |
| S-1 · Registration statement | Jan 5, 2024 |
| DRS/A · Draft registration statement, amended | Dec 6, 2023 |
| DRSLTR · Letter to the SEC with a draft | Dec 5, 2023 |
| UPLOAD · Letter from the SEC | Nov 15, 2023 |
| DRSLTR · Letter to the SEC with a draft | Oct 31, 2023 |
| DRS/A · Draft registration statement, amended | Oct 31, 2023 |
| UPLOAD · Letter from the SEC | Oct 18, 2023 |
| DRSLTR · Letter to the SEC with a draft | Oct 4, 2023 |
| DRS/A · Draft registration statement, amended | Oct 4, 2023 |
| UPLOAD · Letter from the SEC | Sep 27, 2023 |
| DRS · Draft registration statement | Aug 25, 2023 |
Open IPO · From the cover of the final prospectus (424B4) filed Jan 26, 2024
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2025 | FY2024 | FY2024 | FY2023 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | ||||
| Research and development | 153.4M | 153.4M | 79.0M | 79.0M | 64.9M | 64.9M | 30.4M | 6.43M |
| Selling, general and administrative | 24.2M | 15.3M | 9.71M | 6.47M | 3.02M | |||
| Operating income | -177.5M | -177.5M | -94.3M | -94.3M | -74.6M | -74.6M | -36.9M | -8.70M |
| Depreciation and amortization | -3.03M | 3.03M | 36.9M | 11.6M | ||||
| EBITDA | -180.6M | -174.5M | 0 | 2.90M | ||||
| Income before tax | -166.3M | -80.5M | -69.3M | -36.9M | -51.6M | |||
| Income tax | -80.5M | -36.9M | -11.6M | |||||
| Net income | -166.3M | -166.3M | -80.5M | -80.5M | -69.3M | -69.3M | -36.9M | -51.6M |
| Earnings per share, basic | -4.32 | -4.32 | -2.56 | -2.56 | -32.38 | -2.17 | -1.10 | -40.44 |
| Earnings per share, diluted | -4.32 | -2.56 | -32.38 |
Balance sheet
| Line | FY2025 | FY2025 | FY2024 | FY2024 | FY2023 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 45.5M | 45.5M | 74.3M | 74.3M | 150.4M | 150.4M | 163.4M | 37.3M |
| Short-term investments | 267.3M | 267.3M | 144.6M | 144.6M | 0 | |||
| Receivables | 60.0K | 500.0K | 761.0K | 500.0K | 250.0K | |||
| Inventory | -240.0K | |||||||
| Current assets | 332.9M | 332.9M | 227.0M | 227.0M | 160.0M | 160.0M | 182.6M | 43.0M |
| Total assets | 333.2M | 333.2M | 274.9M | 274.9M | 163.1M | 163.1M | 182.8M | 43.0M |
| Accounts payable | 5.93M | 5.93M | 3.78M | 3.78M | 4.53M | 4.53M | 3.09M | 293.0K |
| Current liabilities | 25.9M | 25.9M | 17.3M | 17.3M | 11.6M | 11.6M | 8.36M | 1.82M |
| Total debt | 14.0K | 176.0K | 317.0K | 139.0K | ||||
| Total liabilities | 25.9M | 25.9M | 17.3M | 17.3M | 11.8M | 11.8M | 8.37M | 1.82M |
| Shareholders' equity | 307.2M | 307.2M | 257.7M | 257.7M | -153.2M | 151.3M | 174.5M | 41.2M |
| Shares outstanding | 42.5M | 38.5M | 33.7M | 31.5M | 2.75M | 32.0M | 33.5M | 1.28M |
Cash flow
| Line | FY2025 | FY2025 | FY2024 | FY2024 | FY2023 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -160.6M | -160.6M | -70.2M | -70.2M | -55.8M | -55.8M | -43.6M | -12.6M |
| Capital spending | 0 | 0 | 0 | 0 | 0 | |||
| Free cash flow | -160.6M | -70.2M | -55.8M | -43.6M | -12.6M | |||
| Cash from investing | -71.2M | -71.2M | -192.5M | -192.5M | -40.0M | |||
| Cash from financing | 203.1M | 203.1M | 186.6M | 186.6M | 42.9M | 42.9M | 169.7M | 89.9M |
| Change in cash | -28.8M | -28.8M | -76.1M | -76.1M | -13.0M | -13.0M | 126.1M | 37.3M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 9, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 2, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 26, 2026 | Current report | SEC |
| 8-K · Current report | Oct 19, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Oct 13, 2026 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 8, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Oct 6, 2026 | Current report | SEC |
All 162 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Aug 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 22, 2026 | Meeting outcome | SEC |
| 8-K · Current report | May 11, 2026 | Current report | SEC |
| 424B5 · Prospectus | May 11, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 11, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 6, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 28, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2026 | Meeting notice | SEC |
| 8-K · Current report | Mar 17, 2026 | Current report | SEC |
| S-8 · Registration statement for employee plans | Mar 5, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 5, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 5, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 5, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 30, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 21, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 10, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 30, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 17, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 15, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Sep 9, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 13, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 13, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 11, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2025 | Results | SEC |
| 8-K · Current report | Jul 21, 2025 | Current report | SEC |
| 4 · Change in ownership | Jul 15, 2025 | Insider trade | SEC |
| 424B5 · Prospectus | Jul 2, 2025 | Offer document | SEC |
| 8-K · Current report | Jul 2, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Jul 1, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 23, 2025 | Current report | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 20, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2025 | Results | SEC |
| 4 · Change in ownership | Apr 29, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 29, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 28, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 28, 2025 | Management or board change | SEC |
| 8-K · Current report | Mar 13, 2025 | Current report | SEC |
| S-8 · Registration statement for employee plans | Mar 3, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 3, 2025 | Results | SEC |
| 10-K · Annual report | Mar 3, 2025 | Annual report | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| S-3ASR · Registration statement | Feb 3, 2025 | Offer document | SEC |
| 8-K · Current report | Jan 21, 2025 | Material contract | SEC |
| SC 13G · Big-stake notice | Dec 4, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Oct 24, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Oct 11, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 23, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 9, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Aug 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2024 | Results | SEC |
| 8-K/A · Current report, amended | Jul 9, 2024 | Management or board change | SEC |
| 8-K/A · Current report, amended | Jul 9, 2024 | Management or board change | SEC |
| 8-K · Current report | Jun 5, 2024 | Material contract | SEC |
| 4 · Change in ownership | May 20, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 20, 2024 | Insider trade | SEC |
| 8-K · Current report | May 16, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | May 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2024 | Results | SEC |
| 4 · Change in ownership | Apr 23, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 23, 2024 | Insider trade | SEC |
| 8-K · Current report | Apr 22, 2024 | Management or board change | SEC |
| 10-K · Annual report | Mar 28, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 28, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13D · Big-stake notice | Feb 5, 2024 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Feb 2, 2024 | Offer document | SEC |
| 4 · Change in ownership | Feb 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 31, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 30, 2024 | Current report | SEC |
| SEC STAFF LETTER | Jan 30, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jan 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 29, 2024 | Insider trade | SEC |
| 424B4 · Prospectus | Jan 26, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jan 26, 2024 | Other filings | SEC |
| 3 · Initial statement of ownership | Jan 25, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 25, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 25, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 25, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 25, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 25, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 25, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 25, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 25, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 25, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 25, 2024 | Insider trade | SEC |
| S-1MEF · Registration of more shares for the same offering | Jan 25, 2024 | Offer document | SEC |
| CERT · Exchange's certificate of listing | Jan 25, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jan 23, 2024 | Offer document | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Jan 23, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 23, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 23, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 22, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jan 22, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jan 12, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 11, 2024 | Other filings | SEC |
| S-1 · Registration statement | Jan 5, 2024 | Offer document | SEC |
| DRSLTR · Letter to the SEC with a draft | Dec 5, 2023 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Dec 5, 2023 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Nov 15, 2023 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | Oct 31, 2023 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Oct 31, 2023 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Oct 18, 2023 | Other filings | SEC |
| SEC STAFF LETTER | Oct 13, 2023 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | Oct 4, 2023 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Oct 4, 2023 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Sep 27, 2023 | Other filings | SEC |
| DRS · Draft registration statement | Aug 25, 2023 | Offer document | SEC |
| D | Dec 29, 2022 | Other filings | SEC |
| D/A | Feb 14, 2022 | Other filings | SEC |
| D | Jun 23, 2021 | Other filings | SEC |
Cap table
Built by 6ix from ArriVent BioPharma, Inc.’s releases · as of Nov 5, 2026
- Common shares
- 51,723,074
- Fully diluted
- 51,723,074
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 51,723,074 | Nov 5, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 5, 2026 | 51,723,074 |
| Sep 30, 2026 | 51,212,170 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Carl Gordon Other companies: ADARx Pharmaceuticals, Inc. (Co-head Global Private Equity at OrbiMed Advisors · Since at least Sep 24, 2026); Electra Therapeutics, Inc. (Director · Since at least Sep 18, 2026); BlossomHill Therapeutics, Inc. (Board Member · Since at least Aug 6, 2026); Scribe Therapeutics Inc. (Director · Since at least Jul 23, 2026); Compass Therapeutics, Inc. (Founding Member, Managing Partner, and Co-Head of Global Private Equity, OrbiMed Advisors LLC · Since at least Jun 17, 2020); Keros Therapeutics, Inc. (Director · Since at least Apr 7, 2020); MBX Biosciences, Inc. (Director · Sep 12, 2024 – Feb 14, 2025 · Past); Theseus Pharmaceuticals Inc (Director · Oct 6, 2021 – Feb 14, 2024 · Past); Disc Medicine, Inc. (Director · Feb 5, 2021 – Oct 4, 2021 · Past); Terns Pharmaceuticals, Inc. (Director · Feb 4, 2021 – Jul 15, 2024 · Past); Kinnate Biopharma Inc (Director · Dec 2, 2020 – Apr 3, 2024 · Past); Adicet Bio, Inc. (Director · Sep 15, 2020 – Aug 21, 2024 · Past); ORIC Pharmaceuticals, Inc. (Director · Apr 23, 2020 – Jun 16, 2021 · Past); SpringWorks Therapeutics Inc (Director · Sep 12, 2019 – Sep 12, 2019 · Past); Prevail Therapeutics Inc (Director · Jun 19, 2019 – Jan 22, 2021 · Past); Turning Point Therapeutics Inc (Director · Apr 16, 2019 – Jun 15, 2020 · Past); Alector, Inc. (Director · Feb 6, 2019 – May 10, 2019 · Past); Armo Biosciences Inc. (Director · Jan 25, 2018 – Jun 22, 2018 · Past); X4 Pharmaceuticals, Inc. (Director · Nov 15, 2017 – Jun 5, 2018 · Past); Cartesian Therapeutics, Inc. (Director · Jun 21, 2016 – Jun 27, 2016 · Past); Intellia Therapeutics, Inc. (Director · May 5, 2016 – May 18, 2017 · Past); Acceleron Pharma Inc (Director · Sep 18, 2013 – Sep 18, 2013 · Past); Pacira BioSciences, Inc. (Director · Feb 2, 2011 – Feb 8, 2011 · Past); Amarin Corporation plc (Director · Dec 30, 2010 – Sep 4, 2012 · Past); BioCryst Pharmaceuticals, Inc. (Director · May 17, 2006 – May 17, 2006 · Past) | Director · Jan 25, 2024 – Jan 30, 2024 · Past |
| James Healy Other companies: Seaport Therapeutics, Inc. (Director · Since at least Apr 30, 2026); BioAge Labs, Inc. (Director · Since at least Sep 25, 2024); Rapport Therapeutics, Inc. (Director · Since at least Jun 6, 2024); Y mAbs Therapeutics (Director · Since at least Sep 20, 2018); CinCor Pharma Inc (Director · Jan 6, 2022 – Nov 28, 2022 · Past); Bolt Biotherapeutics, Inc. (Director · Feb 4, 2021 – Jun 12, 2024 · Past); Karuna Therapeutics Inc (Director · Jun 27, 2019 – Mar 18, 2024 · Past); PDS Biotechnology Corporation (Director · Sep 30, 2015 – Jun 20, 2017 · Past); Natera, Inc. (Director · Jul 1, 2015 – Apr 25, 2025 · Past); Coherus Oncology, Inc. (Director · Nov 6, 2014 – Jan 7, 2022 · Past); Humanigen Inc (Director · Aug 10, 2012 – Apr 30, 2013 · Past); Hyperion Therapeutics Inc (Director · Jul 25, 2012 – May 7, 2015 · Past); Durata Therapeutics Inc (Director · Jul 18, 2012 – Jul 24, 2012 · Past); Amarin Corporation plc (Director · Dec 30, 2010 – Jul 11, 2016 · Past); Anthera Pharmaceuticals Inc (Director · Feb 23, 2010 – May 17, 2013 · Past); Paratek Pharmaceuticals Inc (Director · May 9, 2006 – Feb 13, 2008 · Past); InterMune Inc (Director · Dec 31, 2005 – Sep 29, 2014 · Past) | Director · Since at least Jan 25, 2024 |
| Kristine Peterson Other companies: Mineralys Therapeutics, Inc. (Board Member · Since at least Oct 19, 2026); Immunocore Holdings plc (Non-Executive Director · Since at least Jan 2, 2024); Enanta Pharmaceuticals, Inc. (Director · Since at least Sep 11, 2017); EyePoint, Inc. (Director · Jun 27, 2017 – Feb 28, 2020 · Past); Paratek Pharmaceuticals Inc (Director · Mar 2, 2016 – Sep 21, 2023 · Past); ImmunoGen Inc (Director · Jan 30, 2012 – Feb 12, 2024 · Past); Amarin Corporation plc (Director · Dec 30, 2010 – Jun 27, 2022 · Past) | Lead Independent Director · Since at least Apr 20, 2024 |
| John Hohneker Other companies: Curis, Inc. (Director · Since at least Dec 2, 2021); Carisma Therapeutics, Inc. (Director · Apr 1, 2024 – Jun 26, 2024 · Past); Humanigen Inc (Director · Oct 19, 2021 – Jul 27, 2022 · Past); Aravive Inc (Director · May 12, 2021 – Sep 23, 2022 · Past); Evelo Biosciences, Inc. (Director · Jan 27, 2021 – Jun 8, 2023 · Past); Dimension Therapeutics (Director · Jan 18, 2017 – Nov 7, 2017 · Past) | Director · Since at least May 16, 2024 |
| Chris Nolet Other companies: Jasper Therapeutics, Inc. (Director · Since at least Sep 24, 2021); PolarityTE Inc. (Director · Apr 6, 2020 – Jan 12, 2023 · Past); Viela Bio Inc (Director · Oct 2, 2019 – Mar 15, 2021 · Past); Revance Therapeutics, Inc. (Director · Jul 16, 2019 – Feb 4, 2025 · Past) | Director · Since at least Jan 25, 2024 |
| Merdad Parsey Other companies: Ardelyx, Inc. (Director · Since at least Apr 28, 2025); Sagimet Biosciences Inc. - Series A (Director · Jul 13, 2023 – Jun 5, 2024 · Past); Arcus Biosciences, Inc. (Director · Jul 13, 2020 – Jul 13, 2020 · Past); Gilead Sciences, Inc. (Chief Medical Officer · Nov 1, 2019 – Dec 10, 2024 · Past) | Director · Since at least Apr 28, 2025 |
| Zhengbin Yao Other companies: Alumis Inc. (Director · Since at least Jun 27, 2024); NexImmune, Inc. (Director · Feb 11, 2021 – Jul 5, 2023 · Past); Viela Bio Inc (Chief Executive Officer, Director · Oct 2, 2019 – Mar 13, 2021 · Past); Tanox Inc (Vice President of Research · Feb 15, 2006 – Nov 20, 2006 · Past) | Chairman, Chief Executive Officer · Since at least Jan 25, 2024 |
| Bahija Jallal Other companies: Immunocore Holdings plc (Chief Executive Officer · Since at least Jan 2, 2024); Elevance Health, Inc. (Director · Since at least Feb 1, 2018); Guardant Health, Inc. (Director · Apr 17, 2019 – Jun 15, 2022 · Past) | Director · Jan 25, 2024 – Jan 25, 2024 · Past |
| Winston Kung Other companies: Corbus Pharmaceuticals Holdings, Inc. (Director · Since at least Aug 16, 2024); Janux Therapeutics, Inc. (Director · Since at least Sep 21, 2022); PMV Pharmaceuticals, Inc. (COO, CFO · Sep 24, 2020 – May 12, 2023 · Past) | Chief Financial Officer · Since at least Jan 25, 2024 |
| James Kastenmayer Other companies: Spyre Therapeutics, Inc. (General Counsel · Aug 23, 2022 – Feb 23, 2023 · Past); Viela Bio Inc (General Counsel · Jan 6, 2020 – Mar 15, 2021 · Past) | General Counsel · Since at least Jan 25, 2024 |
All 15 people
| Person | Seat |
|---|---|
| Brent Rice | Chief Commercial Officer · Since at least Nov 10, 2025 |
| Chris Nolet | Director · Since at least Nov 4, 2026 |
| Robin LaChapelle | Chief Operating Officer · Since at least Jan 25, 2024 |
| Stuart Lutzker | Director · Since at least Jan 25, 2024 |
| Yang Wang | Chief Technology Officer · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about ArriVent BioPharma, Inc.